Alnylam Pharmaceuticals reported $40.81M in Cost of Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 2.67M 0.28M
Agios Pharmaceuticals AGIO:US $ 0.44M 0.1M
Alnylam Pharmaceuticals ALNY:US $ 40.81M 5.18M
Amgen AMGN:US $ 1510M 51M
Biocryst Pharmaceuticals BCRX:US $ 0.25M 0.01M
Biomarin Pharmaceutical BMRN:US $ 123.13M 6.16M
Bluebird Bio BLUE:US $ 1.74M 6.56M
Intercept Pharmaceuticals ICPT:US $ 0.31M 0.45M
IONIS PHARMACEUT IONS:US $ 4.17M 1.94M
Moderna Inc MRNA:US 1.38B 364M
Neurocrine Biosciences NBIX:US $ 4.8M 0.2M
Novartis NVS:US $ 3749M 6M
Ptc Therapeutics PTCT:US $ 9.64M 0.5M
Regeneron Pharmaceuticals REGN:US $ 297.1M 107.8M
Sarepta Therapeutics SRPT:US $ 37.8M 6.35M
Takeda 4502:JP Y 292882M 15498M
Ultragenyx Pharmaceutical RARE:US $ 8.27M 2.17M
Vertex Pharmaceuticals VRTX:US $ 261.8M 16M
YTE INCY:US $ 45.24M 8.02M